(anemia)
A Novel Approach to Treatment for Urinary Incontinence Among Women with Obesity and Type 2 Diabetes Mellitus Study IRB#:2000037918 Last Updated:07/12/2026 We are recruiting participants for an observational research study to see whether GLP-1 agonists, medications like Ozempic and Wegovy used to treat obesity and diabetes, may help to improve urinary incontinence
A commenter noted investing more than $7.5 million over 6+ years for two seminal RCTs, stating such investment in post-FDA studies alone exceeds application fees of both PMA and BLA products but is not captured in CMS' FDA pathway analysis
These treatments often pair standard medications with GLP-1 agents to improve weight loss outcomes
Relevant disclosures: AbbVie, Alcon, Aldeyra, Bausch & Lomb, Harrow, Johnson & Johnson, Mallinckrodt, Oasis, Oyster Point, Tarsus, Thea, Viatris More Articles by John D
Employers may vary coverage by benefit: some cover GLP-1s only for diabetes (with weight loss as a secondary benefit), or cover weight loss meds only via the pharmacy benefit if a specific BMI is documented
